FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Stéphanie Rolin

Research Profile

Chemicals & Drugs

Physiology

Platelet Aggregation

Anatomy

Living Beings

Disorders

Animal Disease Models

Co-author Network

Publications

TOP 3
Céline Cherdon; Stéphanie Rolin; Julien Hanson; Annie Ooms; Laurence de Leval; Pierre Drion; Carine Michiels; Bernard Pirotte; Bernard Masereel; N Sakalihassan; Jean-Olivier Defraigne; Jean-Michel Dogné
BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase.
Stéphanie Rolin; Julien Hanson; Caroline Vastersaegher; C Cherdon; Domenico Pratico'; Bernard Masereel; Jean-Michel Dogne
BM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2alphain vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents.
Lieve Lanoye; Patrick Segers; Vincent Tchana-Sato; Stéphanie Rolin; Jean-Michel Dogne; Alexandre Ghuysen; Bernard Lambermont; Julien Hanson; Thomas Desaive; Pascal Verdonck; Vincent D'Orio; Philippe Kolh
Cardiovascular haemodynamics and ventriculo-arterial coupling in an acute pig model of coronary ischaemia-reperfusion.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Stéphanie Rolin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Céline Cherdon; Stéphanie Rolin; Julien Hanson; Annie Ooms; Laurence de Leval; Pierre Drion; Carine Michiels; Bernard Pirotte; Bernard Masereel; N Sakalihassan; Jean-Olivier Defraigne; Jean-Michel Dogné
BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase.
Prostaglandins & other lipid mediators 2011;94(3-4):124-32.
2007: Stéphanie Rolin; Julien Hanson; Caroline Vastersaegher; C Cherdon; Domenico Pratico'; Bernard Masereel; Jean-Michel Dogne
BM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2alphain vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents.
Prostaglandins & other lipid mediators 2007;84(1-2):14-23.
2007: Lieve Lanoye; Patrick Segers; Vincent Tchana-Sato; Stéphanie Rolin; Jean-Michel Dogne; Alexandre Ghuysen; Bernard Lambermont; Julien Hanson; Thomas Desaive; Pascal Verdonck; Vincent D'Orio; Philippe Kolh
Cardiovascular haemodynamics and ventriculo-arterial coupling in an acute pig model of coronary ischaemia-reperfusion.
Experimental physiology 2007;92(1):127-37.
2006: Stéphanie Rolin; Bernard Masereel; Jean-Michel Dogné
Prostanoids as pharmacological targets in COPD and asthma.
European journal of pharmacology 2006;533(1-3):89-100.
2006: Philippe Kolh; Stéphanie Rolin; Vincent Tchana-Sato; Michel Pétein; Alexandre Ghuysen; Bernard Lambermont; Julien Hanson; David Magis; Patrick Segers; Bernard Masereel; Vincent D'Orio; Jean-Michel Dogne
Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion.
Prostaglandins & other lipid mediators 2006;79(1-2):53-73.
2006: Marie P Gauthier; Catherine Michaux; Stéphanie Rolin; Caroline Vastersaegher; Xavier de Leval; Fabien Julémont; Lionel Pochet; Bernard Masereel
Synthesis, molecular modelling and enzymatic evaluation of (+/-)3,5-diphenyl-2-thioxoimidazolidin-4-ones as new potential cyclooxygenase inhibitors.
Bioorganic & medicinal chemistry 2006;14(4):918-27.
2005: Julien Hanson; Stéphanie Rolin; Denis Reynaud; Na Qiao; Leanne P Kelley; Helen M Reid; François Valentin; John R Tippins; B Therese Kinsella; Bernard Masereel; Cecil R Pace-Asciak; Bernard Pirotte; Jean-Michel Dogné
In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
The Journal of pharmacology and experimental therapeutics 2005;313(1):293-301.
2005: Jean-Michel Dogné; Stéphanie Rolin; Michel Pétein; Vincent Tchana-Sato; Alexandre Ghuysen; Bernard Lambermont; Julien Hanson; David Magis; Patrick Segers; Bernard Pirotte; Bernard Masereel; Pierre Drion; Vincent D'Orio; Philippe Kolh
Characterization of an original model of myocardial infarction provoked by coronary artery thrombosis induced by ferric chloride in pig.
Thrombosis research 2005;116(5):431-42.
2005: Alexandre Ghuysen; Jean-Michel Dogné; Patrice Chiap; Stéphanie Rolin; Bernard Masereel; Bernard Lambermont; Philippe Kolh; Vincent Tchana-Sato; Julien Hanson; Vincent D'Orio
Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor.
Cardiovascular drug reviews 2005;23(1):1-14.
2004: Celine Chazalette; Bernard Masereel; Stéphanie Rolin; Anne Thiry; Andrea Scozzafava; Alessio Innocenti; Claudiu T Supuran
Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties.
Bioorganic & medicinal chemistry letters 2004;14(23):5781-6.
2004: Stéphanie Rolin; Jean-Michel Dogne; Caroline Vastersaegher; Julien Hanson; Bernard Masereel
Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors.
Prostaglandins & other lipid mediators 2004;74(1-4):75-86.
2004: Marc A Ilies; Bernard Masereel; Stéphanie Rolin; Andrea Scozzafava; Gheorghe Câmpeanu; Valentin Cîmpeanu; Claudiu T Supuran
Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity.
Bioorganic & medicinal chemistry 2004;12(10):2717-26.
2004: Jean-Michel Dogné; Julien Hanson; Xavier de Leval; Philippe Kolh; Vincent Tchana-Sato; Laurence de Leval; Stéphanie Rolin; Alexandre Ghuysen; Patrick Segers; Bernard Lambermont; Bernard Masereel; Bernard Pirotte
Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
The Journal of pharmacology and experimental therapeutics 2004;309(2):498-505.
2003: Catherine Michaux; Jean-Michel Dogné; Stéphanie Rolin; Bernard Masereel; Johan Wouters; François Durant
A pharmacophore model for sulphonyl-urea (-cyanoguanidine) compounds with dual action, thromboxane receptor antagonists and thromboxane synthase inhibitors.
European journal of medicinal chemistry 2003;38(7-8):703-10.
2003: Stéphanie Rolin; M Petein; Vincent Tchana-Sato; Jean-Michel Dogne; Patricia Benoit; Bernard Lambermont; Alexandre Ghuysen; Philippe Kolh; Bernard Masereel
BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis.
The Journal of pharmacology and experimental therapeutics 2003;306(1):59-65.
2003: Jean-Michel Dogné; Xavier de Leval; Philippe Kolh; V Sanna; Stéphanie Rolin; Catherine Michaux; M Mauer; Jean-Louis David; Bernard Masereel; Bernard Pirotte
Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function.
Prostaglandins, leukotrienes, and essential fatty acids 2003;68(1):49-54.
2002: Jean-Michel Dogné; Xavier de Leval; Patricia Benoit; Stéphanie Rolin; Bernard Pirotte; Bernard Masereel
Therapeutic potential of thromboxane inhibitors in asthma.
Expert opinion on investigational drugs 2002;11(2):275-81.
2002: Bernard Masereel; Stéphanie Rolin; Francesco Abbate; Andrea Scozzafava; Claudiu T Supuran
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties.
Journal of medicinal chemistry 2002;45(2):312-20.
2001: Stéphanie Rolin; Jean-Michel Dogné; Catherine Michaux; Jacques Delarge; Bernard Masereel
Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles.
Prostaglandins, leukotrienes, and essential fatty acids 2001;65(2):67-72.
2001: Jean-Michel Dogné; Johan Wouters; Stéphanie Rolin; Catherine Michaux; Lionel Pochet; François Durant; Jacques Delarge; Bernard Masereel
Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor.
The Journal of pharmacy and pharmacology 2001;53(5):669-80.
2001: Catherine Michaux; Stéphanie Rolin; Jean-Michel Dogné; François Durant; Bernard Masereel; Jacques Delarge; Johan Wouters
Structure determination and comparison of BM567, a sulfonylurea, with terbogrel, two compounds with dual action, thromboxane receptor antagonism and thromboxane synthase inhibition.
Bioorganic & medicinal chemistry letters 2001;11(8):1019-22.
2001: Jean-Michel Dogné; Stéphanie Rolin; Xavier de Leval; Patricia Benoit; P Neven; Jacques Delarge; Philippe Kolh; Jacques Damas; Jean-Louis David; Bernard Masereel
Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531.
Cardiovascular drug reviews 2001;19(2):87-96.
2000: Jean-Michel Dogné; Xavier de Leval; P Neven; Stéphanie Rolin; J Wauters; Jean-Louis David; Jacques Delarge; B Massereel
Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function.
Prostaglandins, leukotrienes, and essential fatty acids 2000;62(5):311-7.
1999: Jean-Michel Dogné; P Neven; Jacques Damas; J Fontaine; Stéphanie Rolin; Xavier de Leval; Jacques Delarge; Bernard Masereel
BM 144: an original thromboxane A2 receptor antagonist derived from torasemide.
Journal de pharmacie de Belgique 1999;54(2):57-8.